European AIDS Treatment Group

EU Civil Society Forum (CSF) on HIV , TB and Hepatitis
EU Civil Society Forum on Drugs
WHO Regional Coordination Committee on HIV, TB and Hep
AIDS Action Europe;
European Public Health Alliance (EPHA);
European Forum for Good Clinical Practice (EFGCP)
European Patient Forum (EPF)
Platform for Cooperation with undocumented migrants (PICUM)
ILGA – Europe
International Committee on Rights of Sex Workers (ICRSE)

None declared

Jan 2020 - Dec 2020

37,500€

222,670 € (Source: H2020 IMI)

None declared

Commission expert group - Civil Society Forum on Drugs#E02681#http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2681 #Member #C#Civil society#Sub-group on Relations with International Institutions

N/A

EU Civil Society forum on HIV, TB and Hepatitis coordination with AAE, EHRA, Correlations, TBEC. EATG act as secretariat together with AAE.
HIVACAR – EVALUATING A COMBINATION OF IMMUNE-BASED THERAPIES TO ACHIEVE A FUNCTIONAL CURE OF HIV INFECTION. The project aims to change the current paradigm of HIV treatment by obtaining a functional cure for HIV thanks to effectively targeting residual virus replication and viral reservoirs.
EHVA – EUROPEAN HIV VACCINE ALLIANCE, AN EU PLATFORM FOR THE DISCOVERY AND EVALUATION OF NOVEL PROPHYLACTIC AND THERAPEUTIC VACCINE CANDIDATES. Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.
PROMs in HIV Research and Development: Analysis of Community Needs and Engagement - In March 2021 EATG launched the report on the use of Patient Reported Outcome Measures (PROMs) for the development of new HIV medicines. Led by the community, the work comprised of a literature review, a survey with people living with HIV taking treatment and stakeholder interviews. The purpose of the work is to describe the current use of PROMs in HIV research and development as well as to inform an advocacy agenda to guide the use and development of PROMs, highlighting the role of communities living with or affected by HIV. It provides a concrete set of recommendations for people living with HIV, pharmaceutical companies, researchers/clinicians and regulatory bodies/HTAs.
https://bit.ly/eatg-promise-leaflet https://bit.ly/eatg-promise-booklet https://bit.ly/eatg-promise-referencepaper
From Mar 2020 to Jan 2021, EATG documented the impact of the disruption caused by the SARS-COV2 pandemic on people living with or most affected by HIV and solutions found to mitigate it, including at community level. EATG published 6 bulletins, organised mutual learning e-meetings on HIV self-testing, ensuring continuity in sexual health services, COVID-19 vaccines, adaptation of services at community level. It presented findings at scientific conferences and a WHO-ECDC meeting on national HIV and Hepatitis coordinators. It was also part of the working group of EuroTEST (eurotest.org) to assess the impact of the crisis on HIV, TB, viral hepatitis and STIs testing survey. https://linktr.ee/eatgcovid19
From Mar 2020 to Apr 2021, EATG conducted a desk research on the interplay of mental health, well-being and HIV. The desk research included a literature review as well as a European-wide survey on the community perspective on the role of mental health in HIV prevention, treatment adherence, quality of life and retention in care. The reports will be launched at a multistakeholder meeting starting in April 2021. A workshop focusing on key thematic areas that were identified in the research was organised in Jan 2021, to elaborate specific recommendations on practical interventions in community and healthcare settings that can effectively address the key elements of the interplay of mental health and HIV. A briefing paper capturing the elaborated recommendations will also be discussed during the first part of the multistakeholder meeting.
In 2020, as part of the EmERGE project (https://www.emergeproject.eu), EATG worked on two publications: 1 “Policy and practice guidelines: Report on guidelines to support co-design for improved usability, acceptability and patient outcomes in mHealth developments” and 2) “How EmERGE addressed barriers to the implementation of mHealth”, which looked at barriers that exist when implementing mHealth solutions and how the EmERGE project was able to anticipate many of these and, where unexpected challenges arose, how the project was able to manage them. The report from the closing policy meeting “Future of mHealth in Europe Lessons learned from the EmERGE project” was published in Sept 2020.

Achievements:
EATG has been at the forefront of community involvement in treatment development in HIV and co-infections. Our models of community involvement are shared with patient organisations beyond the HIV and co-infections field. EATG has been leading on innovative techniques such as biomedical prevention and HIV cure research.
EATG has been actively involved in setting up the EU Civil Society Forum on HIV, hepatitis and TB. Currently we are playing a leading role in the reform of the CSF.
In 1997 EATG created the European Community Advisory Board (ECAB) to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis. Today and in the coming years, these ECABs will remain one of EATG’s core activities. This model of high-level scientific platform has been copied by other national and international community groups and networks (e.g. Portuguese CAB, EECA CAB, TB CAB, Positive Council Switzerland etc.)
Via our ‘Sitges’ meetings, EATG has driven the community input in HCV cure development.
EATG provides capacity building to different stakeholders, thus supporting better networking (especially in Central and Eastern Europe), increased capacity of people living with HIV and health care providers, but also – via follow up activities – direct involvement of these people in new scientific and policy activities.
Population(s) served:
The European AIDS Treatment Group (EATG) is a patient-led NGO that advocates for the rights and interests of people living with or affected by HIV/ AIDS and related co-infections within the WHO Europe region. It is a network of more than 150 members from 45 countries in Europe. Our members are PLHIV and representatives of different communities affected by HIV/AIDS and co-infections. EATG represents the diversity of more than 2.3 million people living with HIV in Europe as well as those affected by HIV/AIDS and co-infections.
Our members are representatives of different communities affected by HIV/AIDS in Europe. Our members are expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena.
EATG has close links with groups and organisations within the area of sex work, drug use, MSM, migrants, prisoners etc. Our work is also in close collaboration with organisations that work on related topics such as vaccine development, prevention, liver disease, sexual health or human rights issues such as stigma and discrimination.
Involvement of people living with HIV :
EATG is a membership driven organisation. Our members are all members of the General Assembly (GA), the highest decision-making body of the EATG. A major part of our members are people living with HIV. The GA is called at least annually by the Board of Directors (BoD). The GA elects the members of the BoD and other bodies. Directors are elected for a period of two years.
HIV positive members are also represented within each part of the structure (selected via democratic systems): Programme Chairs; BoD members, staff and other internal positions. EATG has 3 Programme Areas: Quality of Life, Combination Prevention and Partners in Science. Members become active within one or more of the Programmes, as part of designated Programme Committees or ad hoc task groups. EATG regularly organises consultations with its members and other groups. We actively support the GIPA principle.
Members are the main drivers of our strategic development. With support from the office members, they draft our long-term strategy, set priorities etc. We have many HIV-positive members involved as representatives within different structures and positions such as steering committees, scientific committees, and advisory boards.

2 meetings found. Download meetings

The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

• Date	22 Jul 2019	Location	Brussels
  Subject	Access to medicines
  Cabinet	Cabinet of Commissioner Vytenis Andriukaitis
  Portfolio	Health & Food Safety
  Attending	Arunas Vinciunas (Cabinet member) Vytenis Andriukaitis (Commissioner) Alina Timofte (Cabinet member)
  Other Lobbyists	Association Belge des Consommateurs Test-Achats / Belgische Verbruikersunie Test-Aankoop The European Association of Hospital Pharmacists

• Date	28 Nov 2016	Location	Brussels
  Subject	EU and NGOs action on HIV, TB and Hepatitis
  Cabinet	Cabinet of Commissioner Vytenis Andriukaitis
  Portfolio	Health & Food Safety
  Attending	Paula Duarte Gaspar (Cabinet member) Vytenis Andriukaitis (Commissioner)
  Other Lobbyists	Deutsche Aidshilfe GLOBAL HEALTH ADVOCATES European Liver Patients' Association